Annual General Meeting

Dechra Pharmaceuticals PLC

26 September 2023

 

26 September 2023

Dechra^® Pharmaceuticals PLC

(Dechra, Group, Company)

Date of Announcement of the Preliminary Results for Financial Year ended 30 June 2023
and Annual General Meeting

Dechra announces today that it will release its Preliminary Results for the Financial Year ended 30 June 2023 on 12 October 2023.

The ongoing acquisition of the Company by Freya Bidco Limited remains conditional upon the receipt of antitrust approval in the European Union and foreign direct investment approval in Australia, in each case to the extent required, as well as the sanction of the Scheme by the Court at the Sanction Hearing (each as defined in the scheme document dated 26 June 2023) and is expected to occur in late 2023 or early 2024. As such, Management does not intend to host an analyst briefing and results presentation on this occasion but will, as ever, be available to respond to enquiries.

The Company intends to hold an Annual General Meeting on 13 December 2023, subject to remaining listed at that time.

Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer	Office:  [phone]
Paul Sandland, Chief Financial Officer Jonny Armstrong, Head of Investor Relations e-mail: [e-mail]
TooleyStreet Communications Ltd
Fiona Tooley, Director e-mail: [e-mail]	Mobile: [phone]

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide.  

For more information, please visit: www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH

LEI: 213800J4UVB5OWG8VX82

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

Forward Looking Statement

This document contains certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document.  By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.

 

END